Royalty Pharma plc demonstrated an active strategic positioning, securing numerous deals. The firm got
FDA approval for Schizophrenia medicine, which implies promising revenue streams for their diversified portfolio. They have also solidified their strategic positioning through a lucrative dealings with
Cytokinetics and
Ascendis Pharma. Despite having some shares sold off by institutional shareholders such as
Marshall Wace LLP and
Squarepoint Ops LLC, several other institutional owners and investment firms such as
Evergreen Capital Management LLC and
AE Wealth Management purchased new stakes in Royalty Pharma. Further,
Goldman Sachs elevated the price target for the company's stocks, reaffirming their buy rating. However,
Jim Cramer expressed some concern regarding the company's recent performance. On the positive side, Royalty Pharma's financial results for Q2 2024 beat earnings per share expectations, even though revenues lagged, and the company declared an increased dividend payout compared to the previous year.
Royalty Pharma Stocks News Analytics from Mon, 18 Jun 2018 07:00:00 GMT to Sun, 29 Sep 2024 09:00:56 GMT -
Rating 6
- Innovation 2
- Information 7
- Rumor -6
